Please enable JavaScript or talk to your local administrator to get JavaScript enabled.

Project

Sh3gl2 and chemosensitivity of bladder cancer

Funder: National Cancer Institute

Funding period
USD 492 K
Funding amount
Abstract
Project Abstract Bladder cancer (BCA) is a major cause of cancer-related death worldwide, with grim 5-year survival rates in advanced disease. Standard of care for invasive bladder cancer is radical cystectomy and cisplatin-based chemotherapy. However, metastatic disease remains largely incurable and markers capable of identifying patients who are likely to respond, or not, are currently lacking. Thus, there is an urgent need to identify and characterize the molecular alterations that underlie lethal disease, and to translate this knowledge into novel strategies for BCA management. Recent profiling studies have identified discrete BCA subtypes that display distinct biological behaviors. `Basal'-type bladder cancers are characterized by increased aggressiveness, elevated EGFR pathway activation, and enhanced sensitivity to EGFR-targeted kinase inhibition. However, the mechanisms underlying EGFR activation in BCA remain unknown. New data from our group have identified SH3GL2 (endophilin A1) as a regulator of EGFR-dependent signaling in BCA. Analysis of human BCA specimens revealed a significant loss of SH3GL2 expression with disease progression. SH3GL2 silencing enhanced tumor cell survival and proliferation in vitro, and tumor growth in vivo. SH3GL2 knockdown also increased ligand-induced phosphorylation of the EGFR, SRC family kinases (SFK) and STAT3. Levels of phospho-SRC and phospho-MET were significantly enriched in bladder cancer compared to other tumor types. SH3GL2 silencing was also associated with increased membrane blebbing, a feature of the amoeboid phenotype stimulated by EGFR and MET activation that has been associated with increased tumor aggressiveness. These findings imply that inactivation of SH3GL2 is a novel upstream mechanism for activation of the EGFR, MET and their effector kinases in basal-type BCA. Based on these observations we hypothesize that loss of SH3GL2 sensitizes `basal' BCA to tyrosine kinase inhibitors (TKIs) and may serve as a biomarker of treatment sensitivity. The hypothesis will be tested with the following Specific Aims: (1) Determine the impact of SH3GL2 loss on sensitivity to EGFR and c- MET TKIs. Assays of viability, survival and particle shedding will be used to determine the biological and biochemical consequences of SH3GL2 loss on activation of EGFR/c-MET/effector pathways and sensitivity to TKIs. (2) Determine the association between loss of SH3GL2 and outcome in BCA in vivo. Quantitative multiplex imaging of tissue microarrays from BCA patients will be used to investigate the relationship between SH3GL2 expression activation of EGFR/c-MET and effectors. Orthotopic xenografts will be used to assess the impact of SH3GL2 loss on sensitivity to TKIs in vivo. At the end of the project we will understand the role of SH3GL2 in activation of the EGFR, c-MET and effectors and in sensitization of BCA to TKIs. These studies would provide a point of departure for prospective analyses aimed at determining the utility of SH3GL2 status as an early biomarker for prophylactic TKI-based targeted therapy in BCA.
Similar projects All >
Sorted by: Start Date
Project list item
Targeting TAM (Tyro3-Axl-Mer) family of transmembrane receptor tyrosine kinases in bladder cancer.

Bladder Cancer Advocacy Network to Arpita Roy

USD 1,700
2018 - 2018
Project list item
Novel Biomarkers for the Clinical Management of Bladder Cancer

National Cancer Institute to VINATA B LOKESHWAR

USD 902,622
2018 - 2023
Project list item
Subtyping Bladder Cancer: A Multi-omic, Exposure-informed, Genealogical Approach (MErGE)

National Cancer Institute to HEIDI ANNE HANSON

USD 298,810
2018 - 2023
Project list item
New Drug and Technology Assessment in Bladder Cancer: Creation of a Novel Canadian Policy Model for Bladder Cancer

Canadian Institutes of Health Research to Murray Dale Krahn, Girish Satish Kulkarni, William Wai Lun Wong, George Andrew Tomlinson, Nathan Perlis, Wassim Kassouf, Peter Colin Black, Shabbir Muhammad Husayn Alibhai

USD 77,161
2018 - 2019

System

Categories
  • FOR (ANZSRC)

    1112 Oncology and Carcinogenesis

  • RCDC

    Cancer

  • RCDC

    Urologic Diseases

  • HRCS HC

    Cancer

  • HRCS RAC

    2.1 Biological and endogenous factors

  • HRCS RAC

    4.1 Discovery and preclinical testing of markers and technologies

  • Health Research Areas

    Biomedical

  • Broad Research Areas

    Clinical Medicine and Science